The effect of green tea (Camellia sinensis) on lipid profiles and renal function in people with type 2 diabetes and nephropathy: a randomized controlled clinical trial
- PMID: 38162524
- PMCID: PMC10755896
- DOI: 10.3389/fnut.2023.1253275
The effect of green tea (Camellia sinensis) on lipid profiles and renal function in people with type 2 diabetes and nephropathy: a randomized controlled clinical trial
Abstract
Introduction: Diabetic nephropathy is one of the most important microvascular complications of diabetes. Despite the modern treatments, herbs or medicinal plants have gained wide attention. One of these herbs is green tea (Camellia sinensis), which may have an impact on renal function, lipid profiles, and HbA1c. However, the evidence for this is unclear and limited. The present study aimed to evaluate the effect of different doses of green tea on these parameters in type 2 diabetes patients (T2DM) with nephropathy.
Methods: Sixty-six individuals with T2DM nephropathy (aged 30-70 years) were randomly assigned to receive three cups of green tea/day (n = 22), two cups of green tea/day (n = 22), and the control group (n = 22) for 12 weeks. Lipid profiles, glycated hemoglobin A1c (HbA1c), and renal markers were measured before and after intervention. Data were analyzed using SPSS software version 23. One-way analysis of variance (ANOVA), least significant difference (LSD) post hoc, and analysis of covariance were used to compare quantitative variables.
Results: In total, 64 participants completed the study. Consuming three cups of infusion green tea per day (7.5 gr) led to a significant reduction in serum levels of total cholesterol (p = 0.009) and HbA1c (p = 0.006) and increased in high-density lipoprotein cholesterol (HDL-C) (p = 0.02) compared with the control group who did not drink green tea. However, no significant differences were observed for other variables.
Conclusion: In general, it was found that drinking three cups of green tea infusion (7.5 gr) per day produced beneficial effects on some lipid profiles and HbA1c without any adverse effects on renal function in patients with T2DM nephropathy. More studies are needed to fully elucidate these findings.
Clinical trial registration: Iranian Registry of Clinical Trials (www.irct.ir) under registry number: IRCT2014020114538N2.
Keywords: diabetic nephropathy; glycated hemoglobin A1c; green tea; kidney function; lipid profiles.
Copyright © 2023 Yazdanpanah, Salehi-Abargouei, Mozaffari and Hemayati.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Effects of Herbal Tea (Non-Camellia sinensis) on Glucose Homeostasis and Serum Lipids in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Nutr Rev. 2024 Jun 18:nuae068. doi: 10.1093/nutrit/nuae068. Online ahead of print. Nutr Rev. 2024. PMID: 38894639
-
Human clinical studies of tea polyphenols in allergy or life style-related diseases.Curr Pharm Des. 2013;19(34):6148-55. doi: 10.2174/1381612811319340009. Curr Pharm Des. 2013. PMID: 23448449 Review.
-
Prospective double-blind crossover study of Camellia sinensis (green tea) in dyslipidemias.Arq Bras Cardiol. 2009 Aug;93(2):128-34. doi: 10.1590/s0066-782x2009000800010. Arq Bras Cardiol. 2009. PMID: 19838489 Clinical Trial.
-
Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome.J Am Coll Nutr. 2010 Feb;29(1):31-40. doi: 10.1080/07315724.2010.10719814. J Am Coll Nutr. 2010. PMID: 20595643 Clinical Trial.
-
Green tea (Camellia sinensis) for the prevention of cancer.Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD005004. doi: 10.1002/14651858.CD005004.pub2. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2020 Mar 2;3:CD005004. doi: 10.1002/14651858.CD005004.pub3. PMID: 19588362 Free PMC article. Updated. Review.
References
-
- Ritz E, Rychlík I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis. (1999) 34:795–808. - PubMed
-
- Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care. (2005) 28:164–76. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources